FDA tells Purell to stop claiming it can prevent flu

Marketing campaign also claims product can prevent ebola spread


The Food and Drug Administration (FDA) told the maker of Purell to discontinue marketing campaigns that includes claims for avoiding flu and ebola, according to an article on The New York Times website.

The campaigns also claim the product can prevent spread of MRSA and norovirus.

The FDA told Gojo Industries that its claims that Purell could reduce the potential for infection or prevent illnesses violated the Federal Food, Drug and Cosmetic Act. 

The agency said it was reclassifying Purell as an unapproved drug, rather than an over-the-counter product.

Read the article.



February 10, 2020


Topic Area: Infection Control


Recent Posts

Rethinking Parking Lot Design at Irvine Heritage Medical Plaza

A new solar installation shows how healthcare facilities can improve parking amenities while boosting energy savings


Repurposing Healthcare Spaces: 5 Critical Questions

Done well, converting existing spaces can trim upfront project costs by up to 40 percent, compared with ground-up construction


Disinfectant Contact Time: The Case for Biofilm Disruption

Contact time, while essential for compliance, does not reliably predict microbial reduction on actual healthcare surfaces.


Rethinking How Healthcare Facilities Fund Construction Projects

Rising costs and competing priorities are driving healthcare organizations to explore new financing arrangements and construction strategies.


Putting Trauma-Informed Design into Practice

Arnold's Place demonstrates how design choices can promote dignity and a sense of control for those experiencing homelessness.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.